Loading organizations...
§ Private Profile · 3801 Lake Boone Trail Suite 100, Raleigh, North Carolina 27607, US.
Medical device developer creating novel embolic protection devices for cardiovascular and peripheral vascular procedures.
Based in Raleigh, North Carolina, Contego Medical develops specialized medical devices that integrate embolic protection technology into cardiovascular and peripheral vascular surgical procedures. The company engineers integrated systems that combine embolic filters with angioplasty balloons and stents, utilizing its CE Mark-approved PALADIN Carotid system to simplify complex interventions and reduce severe patient stroke risks. Operating with a historical headcount of five to ten employees, the privately held enterprise has secured growth capital through multiple financing rounds, including a dedicated $5.6 million Series B funding tranche. The organization is financially backed by institutional venture capital investors such as Hatteras Venture Partners and Mountain Group Partners, while its board of directors features prominent industry executives like Stacy Enxing Seng and Joyce Erony. Contego Medical was originally founded in 2005 by medical professionals Ravish Sachar and Jay Yadav.
Contego Medical has raised $28.0M across 2 funding rounds.
Contego Medical has raised $28.0M in total across 2 funding rounds.
Contego Medical has raised $28.0M in total across 2 funding rounds.
Contego Medical's investors include Hatteras Venture Partners, Lookout Capital, Medical Mutual, Mountain Group Partners.
Contego Medical is a privately held medical device company based in Raleigh, NC, specializing in innovative endovascular devices that integrate embolic protection with treatment functions like balloons or stents on a single catheter.[1][2][3] This platform addresses unmet needs in carotid and peripheral vascular procedures by simplifying workflows, reducing procedure steps, improving patient outcomes, and lowering costs, serving interventional cardiologists and vascular specialists treating conditions like carotid artery stenosis and peripheral artery disease.[1][2][5] Key products include the Paladin® Carotid Post-Dilation Balloon System and Vanguard IEP™ Peripheral Balloon Angioplasty System, both CE marked and commercially available in select European markets since around 2015-2016, with recent U.S. expansion via an exclusive distribution agreement with Medtronic for carotid products.[1][3][5]
The company's growth momentum includes early commercial revenue starting in Q1 2016 (details private), clinical validation from the PERFORMANCE II study showing superior outcomes in carotid artery stenting (CAS), and a shift to broader U.S. market access through Medtronic, positioning it for scaled adoption in revascularization treatments.[3][5]
Founded in 2005, Contego Medical emerged from the vision of interventional cardiologists addressing gaps in embolic protection during endovascular procedures, where traditional methods required separate devices, complicating treatments and limiting patient access.[3] Ravish Sachar, MD, an interventional cardiologist and serial entrepreneur, co-founded and leads as CEO; he has advised multiple medtech firms and brings expertise from prior successes.[1][3] Jay Yadav, MD, a co-founder, further bolstered the team with his track record, including founding CardioMEMS (acquired by St. Jude Medical) and AngioGuard.[1][3]
The idea crystallized around integrating embolic protection directly with treatment tools, gaining early traction with CE Mark approvals for Paladin in Q2 2015 and Vanguard IEP, followed by European sales launch in 2016—pivotal moments that validated the technology and attracted venture capital for majority ownership.[1][3]
Contego stands out in the crowded medtech space through its integrated platform technology, which combines embolic protection with therapeutic functions (e.g., balloon dilation or stenting) on one catheter, enabling single-step procedures versus multi-device approaches.[1][2][3]
These features position Contego as a leader in patient-centric vascular interventions.[2][4]
Contego rides the wave of advancing endovascular therapies, where rising prevalence of peripheral and carotid vascular diseases—driven by aging populations and diabetes—demands safer, more efficient alternatives to open surgery.[1][2] Timing aligns with regulatory progress (CE marks) and partnerships like Medtronic, capitalizing on market forces such as reimbursement tailwinds for CAS and growing evidence for embolic protection to prevent periprocedural strokes.[5]
In the ecosystem, Contego influences medtech by pioneering integrated devices, potentially setting new standards of care and enabling broader embolic protection use, while validating clinician-founder models from serial entrepreneurs like Sachar and Yadav.[1][3] This counters fragmented legacy tools, fostering procedural simplification amid consolidation in vascular medtech.
Contego's Medtronic partnership marks a commercialization inflection, likely driving U.S. revenue growth and further trials to cement PERFORMANCE II data against competitors. Trends like AI-guided imaging and bioresorbable tech could enhance its platform, while expanding peripheral indications sustains momentum. Its influence may evolve from niche innovator to category leader, simplifying endovascular care as demographics amplify demand—echoing its founding promise of better outcomes through integration.[5]
Contego Medical has raised $28.0M across 2 funding rounds. Most recently, it raised $22.0M Other Equity in January 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2020 | $22M Venture Round | — | — | Announced |
| Apr 1, 2015 | $6M Series B | Hatteras Venture Partners | Lookout Capital, Medical Mutual, Mountain Group Partners | Announced |